Search

Your search keyword '"Mauriac L"' showing total 97 results
Start Over Author "Mauriac L" Publisher elsevier bv
97 results on '"Mauriac L"'

1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Author

Pivot, Xavier, primary, Romieu, Gilles, additional, Debled, Marc, additional, Pierga, Jean-Yves, additional, Kerbrat, Pierre, additional, Bachelot, Thomas, additional, Lortholary, Alain, additional, Espié, Marc, additional, Fumoleau, Pierre, additional, Serin, Daniel, additional, Jacquin, Jean-Philippe, additional, Jouannaud, Christelle, additional, Rios, Maria, additional, Abadie-Lacourtoisie, Sophie, additional, Venat-Bouvet, Laurence, additional, Cany, Laurent, additional, Catala, Stéphanie, additional, Khayat, David, additional, Gambotti, Laetitia, additional, Pauporté, Iris, additional, Faure-Mercier, Celine, additional, Paget-Bailly, Sophie, additional, Henriques, Julie, additional, Grouin, Jean Marie, additional, Piprot, C, additional, Cals, L, additional, Chaigneau, L, additional, Demarchi, F, additional, N'Guyen, T, additional, Stein, U, additional, Villanueva, C, additional, Bréau, JL, additional, Chouahnia, AK, additional, Saintigny, P, additional, Boué, F, additional, deSaint-Hilaire, P, additional, Guimont, I, additional, Grossat, N, additional, Valenza, B, additional, Lévy, E, additional, Médioni, J, additional, Delbaldo, C, additional, Grenier, J, additional, Pouessel, D, additional, Lavau-Denès, S, additional, Falandry, C, additional, Fournel-Fédérico, C, additional, Freyer, G, additional, Tartas, S, additional, Trillet-Lenoir, V, additional, Bons, F, additional, Auclerc, G, additional, Chièze, S, additional, Raban, N, additional, Tournigand, C, additional, Trager-Maury, S, additional, Bousquet, G, additional, Cuvier, C, additional, Giacchetti, S, additional, Hocini, A, additional, LeMaignan, C, additional, Misset, JL, additional, Avenin, D, additional, Beerblock, C, additional, Gligorov, J, additional, Rivera, P, additional, Roché, H, additional, Bougnoux, P, additional, Hajjaji, N, additional, Capitain, O, additional, Delva, R, additional, Maillart, P, additional, Soulié, P, additional, Bonnefoi, H, additional, Durand, M, additional, Madranges, N, additional, Mauriac, L, additional, Chollet, P, additional, Dillies, AF, additional, Durando, X, additional, Ferrière, JP, additional, Mouret-Reynier, C, additional, Nabholtz, JM, additional, Van Praagh, I, additional, Cottu, P, additional, Diéras, V, additional, Durieux, A, additional, Galotte, M, additional, Girre, V, additional, Henry, S, additional, Iurisci, I, additional, Jouve, M, additional, Laurence, V, additional, Mignot, L, additional, Piperno-Neumann, S, additional, Tresca, P, additional, Coudert, B, additional, Ferrant, E, additional, Mayer, F, additional, Vanneuville, AC, additional, Bonneterre, J, additional, Servent, V, additional, Vanlemmens, L, additional, Vennin, P, additional, Guastalla, JP, additional, Biron, P, additional, Dupuy-Brousseau, L, additional, Lancry, L, additional, Ray-Coquard, I, additional, Rebattu, P, additional, Trédan, O, additional, Extra, JM, additional, Rousseau, F, additional, Tarpin, C, additional, Fabbro, M, additional, Luporsi, E, additional, Uwer, L, additional, Weber, B, additional, Berton-Rigaud, D, additional, Bourbouloux, E, additional, Campone, M, additional, Ferrero, JM, additional, Follana, P, additional, Largillier, R, additional, Mari, V, additional, Costa, B, additional, Curé, H, additional, Eymard, JC, additional, Jovenin, N, additional, Lebrun, D, additional, Meunier, J, additional, Yazbek, G, additional, Gedoin, D, additional, Laguerre, B, additional, Lefeuvre, C, additional, Vauléon, E, additional, Chevrier, A, additional, Guillemet, C, additional, Leheurteur, M, additional, Rigal, O, additional, Tennevet, I, additional, Veyret, C, additional, Brain, E, additional, Guiterrez, M, additional, Mefti-Lacheraf, F, additional, Petit, T, additional, Dalenc, F, additional, Gladieff, L, additional, André, F, additional, Delaloge, S, additional, Domont, J, additional, Ezenfis, J, additional, Spielmann, M, additional, Guillet, P, additional, Boulanger, V, additional, Provençal, J, additional, Stefani, L, additional, Alliot, C, additional, Ré, D, additional, Bellaiche-Miccio, C, additional, Boutan-Laroze, G, additional, Vanica, R, additional, Dion, P, additional, Sadki-Benaoudia, G, additional, Marti, A, additional, Villing, AL, additional, Slama, B, additional, Dutel, JL, additional, Nguyen, S, additional, Saad, R, additional, Arsène, O, additional, Merad-Boudia, Z, additional, Orfeuvre, H, additional, Egreteau, J, additional, Goudier, MJ, additional, Lamy, R, additional, Leduc, B, additional, Sarda, C, additional, Salles, B, additional, Agostini, C, additional, Cauvin, I, additional, Dufresne, A, additional, Mangold, M, additional, Lebouvier-Sadot, S, additional, Audhuy, B, additional, Barats, JC, additional, Cluet-Dennetière, S, additional, Zylberait, D, additional, Netter, G, additional, Gautier-Felizot, L, additional, Cojean-Zelek, I, additional, Plantade, A, additional, Vignot, S, additional, Guardiola, E, additional, Marti, P, additional, deHartingh, I, additional, Diab, R, additional, Dietmann, A, additional, Ruck, S, additional, Portois, C, additional, Oddou-Lagranière, S, additional, Campos-Gazeau, F, additional, Bourcier, A, additional, Priou, F, additional, Geay, JF, additional, Mayeur, D, additional, Gabez, P, additional, ElAmarti, R, additional, Combe, M, additional, Raichon-Patru, P, additional, Amsalhem, P, additional, Dauba, J, additional, Paraiso, D, additional, Guinet, F, additional, Duvert, B, additional, Litor, M, additional, Kara-Slimane, F, additional, Bichoffe, A, additional, Denizon, N, additional, Soyer, P, additional, Morvan, F, additional, Van-Hulst, S, additional, Vincent, L, additional, Alleaume, C, additional, Ibanez-Martin, P, additional, Youssef, A, additional, Tadrist, Z, additional, Carola, E, additional, Pourny, C, additional, Toccanier, JF, additional, Al-Aukla, N, additional, Mahour-Bacha, K, additional, Salvat, J, additional, Nouyrigat, P, additional, Clippe, S, additional, Gouttebel, MC, additional, Vedrine, L, additional, Clavreul, G, additional, Collard, O, additional, Mille, D, additional, Goubely, Y, additional, Hervé, R, additional, Kirscher, S, additional, Plat, F, additional, Delecroix, V, additional, Ligeza-Poisson, V, additional, Coeffic, D, additional, Fric, D, additional, Garnier, C, additional, Leyronnas, C, additional, Kreitman, T, additional, Teissier, E, additional, Martin, P, additional, Rohart deCordoue, S, additional, ElKouri, C, additional, Ramée, JF, additional, Laporte, C, additional, Bernard, O, additional, Altwegg, T, additional, Darut-Jouve, A, additional, Dujols, JP, additional, Darloy, F, additional, Giraud, C, additional, Pottier-Kyndt, V, additional, Achour, N, additional, Drony, S, additional, Moriceau, M, additional, Sarrazin, C, additional, Legueul, JC, additional, Mandet, J, additional, Besson, D, additional, Hardy-Bessard, AC, additional, Cretin, J, additional, Houyau, P, additional, Achille, E, additional, Genêt, D, additional, Thévenot, H, additional, Moran-Ribon, A, additional, Pavlovitch, JM, additional, Ardisson, P, additional, Moullet, I, additional, Couderc, B, additional, Fichet, V, additional, Burki, F, additional, Auliard, A, additional, Levaché, CB, additional, Cailleux, P, additional, Schaeffer, F, additional, Albin, N, additional, Sévin-Robiche, D, additional, Domas, J, additional, Ellis, S, additional, Montcuquet, P, additional, Baumont, GA, additional, Bégue, M, additional, Gréget, S, additional, Ratoanina, JL, additional, Vanoli, A, additional, Bielsa, C, additional, Bonichon-Lamichhane, M, additional, Jaubert, D, additional, Laharie-Mineur, H, additional, Alcaraz, L, additional, Legouffe, E, additional, Bourgeois, H, additional, Cartron, G, additional, Denis, F, additional, Dupuis, O, additional, Ganem, G, additional, Roche-Forestier, S, additional, Delzenne, L, additional, Chirat, E, additional, Baticle, JL, additional, Béguier, E, additional, Jacquot, S, additional, Janssen, E, additional, Lauché, H, additional, LeRol, A, additional, Chantelard, JP, additional, L'Helgoualc'h, GA, additional, Antoine, EC, additional, Kanoui, A, additional, Llory, JF, additional, Vannetzel, JM, additional, Vignoud, J, additional, Bruna, C, additional, Facchini, T, additional, Moutel-Corviole, K, additional, Voloch, A, additional, Ghoul, A, additional, Loiseau, D, additional, Barbet, N, additional, Dohollou, N, additional, and Yakendji, K, additional

Published
2019
Full Text
View/download PDF

2. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

Author

Mauriac, L, Keshaviah, A, Debled, M, Mouridsen, H, Forbes, JF, Thürlimann, B, Paridaens, R, Monnier, A, Láng, I, Wardley, A, Nogaret, JM, Gelber, RD, Castiglione-Gertsch, M, Price, KN, Coates, AS, Smith, I, Viale, G, Rabaglio, M, Zabaznyi, N, Goldhirsch, A, BIG, 1-98 Collaborative Group, and International, Breast Cancer Study Group

Subjects
Oncology, medicine.medical_specialty, Neoplasms, Hormone-Dependent, Time Factors, Antineoplastic Agents, Hormonal, medicine.drug_class, medicine.medical_treatment, Breast Neoplasms, Disease-Free Survival, Breast cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, medicine, Humans, Aromatase, Gynecology, Aromatase inhibitor, biology, Aromatase Inhibitors, business.industry, Letrozole, Hematology, Middle Aged, Triazoles, Prognosis, medicine.disease, Antiestrogen, Postmenopause, Menopause, Tamoxifen, Treatment Outcome, Chemotherapy, Adjuvant, biology.protein, Female, Hormone therapy, Neoplasm Recurrence, Local, business, Follow-Up Studies, medicine.drug
Abstract

BACKGROUND: Aromatase inhibitors are considered standard adjuvant endocrine treatment of postmenopausal women with hormone receptor-positive breast cancer, but it remains uncertain whether aromatase inhibitors should be given upfront or sequentially with tamoxifen. Awaiting results from ongoing randomized trials, we examined prognostic factors of an early relapse among patients in the BIG 1-98 trial to aid in treatment choices. PATIENTS AND METHODS: Analyses included all 7707 eligible patients treated on BIG 1-98. The median follow-up was 2 years, and the primary end point was breast cancer relapse. Cox proportional hazards regression was used to identify prognostic factors. RESULTS: Two hundred and eighty-five patients (3.7%) had an early relapse (3.1% on letrozole, 4.4% on tamoxifen). Predictive factors for early relapse were node positivity (P < 0.001), absence of both receptors being positive (P < 0.001), high tumor grade (P < 0.001), HER-2 overexpression/amplification (P < 0.001), large tumor size (P = 0.001), treatment with tamoxifen (P = 0.002), and vascular invasion (P = 0.02). There were no significant interactions between treatment and the covariates, though letrozole appeared to provide a greater than average reduction in the risk of early relapse in patients with many involved lymph nodes, large tumors, and vascular invasion present. CONCLUSION: Upfront letrozole resulted in significantly fewer early relapses than tamoxifen, even after adjusting for significant prognostic factors.

Published
2007
Full Text
View/download PDF

3. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

Author

Viale, G., primary, Regan, M.M., additional, Dell'Orto, P., additional, Mastropasqua, M.G., additional, Maiorano, E., additional, Rasmussen, B.B., additional, MacGrogan, G., additional, Forbes, J.F., additional, Paridaens, R.J., additional, Colleoni, M., additional, Láng, I., additional, Thürlimann, B., additional, Mouridsen, H., additional, Mauriac, L., additional, Gelber, R.D., additional, Price, K.N., additional, Goldhirsch, A., additional, Gusterson, B.A., additional, and Coates, A.S., additional

Published
2011
Full Text
View/download PDF

4. 5016 POSTER DISCUSSION BIG 1-98 Update: Evaluating Letrozole and Tamoxifen Alone and in Sequence at 8 Years Median Follow-up for Postmenopausal Women With Steroid Hormone Receptor-Positive Breast Cancer

Author

Gelber, R.D., primary, Thiirlimann, B., additional, Giobbie-Hurder, A., additional, Mauriac, L., additional, Ejlertsen, B., additional, Paridaens, R., additional, Price, K.N., additional, Regan, M.M., additional, Coates, A.S., additional, and Goldhirsch, A., additional

Published
2011
Full Text
View/download PDF

10. PTEN Immunohistochemical detection in breast cancer

Author

Macqroqan, G., primary, Bonnet, F., additional, de Mascarel, I., additional, Sevenet, N., additional, Sierankowski, G., additional, Brouste, V., additional, Debled, M., additional, Bonnefoi, H., additional, Mauriac, L., additional, and Longy, M., additional

Published
2008
Full Text
View/download PDF

16. 5BA Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01)

Author

Bonnefoi, H., primary, Potti, A., additional, Mauriac, L., additional, Tubiana-Hulin, M., additional, Campone, M., additional, Cameron, D., additional, Bergh, J., additional, Delorenzi, M., additional, Nevins, J.R., additional, and Iggo, R., additional

Published
2007
Full Text
View/download PDF

19. Carcinomes canalaires in situ bilatéraux: événements indépendants ou maladie bilatérale?

Author

André, G., primary, Tunon-de-Lara, C., additional, Macgrogan, G., additional, Laharie-Mineur, H., additional, Bussieres, J.-E., additional, Valentin, F., additional, Barreau, B., additional, Dilhuydy, M.-H., additional, Dilhuydy, J.-M., additional, Mauriac, L., additional, Debled, M., additional, Durand, M., additional, Mathoulin, S., additional, and Avril, A., additional

Published
2007
Full Text
View/download PDF

30. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer

Author

Hamilton, A., primary, Biganzoli, L., additional, Coleman, R., additional, Mauriac, L., additional, Hennebert, P., additional, Awada, A., additional, Nooij, M., additional, Beex, L., additional, Piccart, M., additional, Van Hoorebeeck, I., additional, Bruning, P., additional, and de Valeriola, D., additional

Published
2002
Full Text
View/download PDF

33. Oral vinorelbine: Feasibility and safety profile

Author

Depierre, A., primary, Freyer, G., additional, Jassem, J., additional, Orfeuvre, H., additional, Ramlau, R., additional, Lemarie, E., additional, Koralewski, P., additional, Mauriac, L., additional, Breton, J.L., additional, Delozier, T., additional, and Trillet-Lenoir, V., additional

Published
2001
Full Text
View/download PDF

35. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

Author

Eiermann, W., primary, Paepke, S., additional, Appfelstaedt, J., additional, Llombart-Cussac, A., additional, Eremin, J., additional, Vinholes, J., additional, Mauriac, L., additional, Ellis, M., additional, Lassus, M., additional, Chaudri-Ross, H.A., additional, Dugan, M., additional, Borgs, M., additional, and Semiglazov, V., additional

Published
2001
Full Text
View/download PDF

36. ICI 182,780 (‘FASLODEX’) is at least as effective as anatrozole (Arimidex™) in post-menopausal women with advanced breast cancer progressing on prior endocrine treatment

Author

Howell, A., primary, Robertson, J.F.R., additional, Albano, J.Quaresma, additional, Aschermannova, A., additional, Mauriac, L., additional, Kleeberg, U.R., additional, Bergote, I., additional, Erikstein, B., additional, Webster, A., additional, and Morris, C., additional

Published
2001
Full Text
View/download PDF

38. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

Author

O’Shaughnessy, J.A., primary, Blum, J., additional, Moiseyenko, V., additional, Jones, S.E., additional, Miles, D., additional, Bell, D., additional, Rosso, R., additional, Mauriac, L., additional, Osterwalder, B., additional, Burger, H.-U., additional, and Laws, S., additional

Published
2001
Full Text
View/download PDF

41. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC)

Author

Leonard, R., primary, Cervantes, G., additional, Lui, W., additional, Mauriac, L., additional, Miles, D., additional, Moiseyenko, V., additional, Chan Navarro, C., additional, Van Hazel, G., additional, Vukelja, S., additional, and O'Shaughnessy, J., additional

Published
2001
Full Text
View/download PDF

44. Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patients

Author

Bonneterre, J., primary, Spielman, M., additional, Guastalla, J.-P., additional, Marty, M., additional, Viens, P., additional, Chollet, P., additional, Roché, H., additional, Fumoleau, P., additional, Mauriac, L., additional, Bourgeois, H., additional, Namer, M., additional, Bergerat, J.P., additional, Misset, J.-L., additional, Trandafir, L., additional, and Mahjoubi, M., additional

Published
1999
Full Text
View/download PDF

45. The added value of the combined evaluation of clinical efficacy, quality of life and cost-effectiveness in a randomized phase III study. Results of an EORTC — NCIC — SAKK neoadjuvant trial in patients with locally advanced breast cancer (LABC)

Author

Therasse, P., primary, Mauriac, L., additional, Welnicka, M., additional, Bruning, P., additional, Cufer, T., additional, Lichinitser, R., additional, Pluzanska, A., additional, Tomiak, E., additional, Koopmanschap, M., additional, and Piccart, M., additional

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results